Biodel Announces Data Presentations at the Diabetes

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Biodel Announces Data Presentations at the Diabetes Technology Society Conference

DANBURY, CT --(Marketwired - October 19, 2015) - Biodel Inc. ( NASDAQ : BIOD ) will present data from studies of its ultra-rapid-acting prandial/basal insulin and Glucagon Emergency Management (GEM) product candidates during the Diabetes Technology Society Conference to be held in Bethesda, MD from October 22 - 24, 2015.

The poster presentation (4:00 pm - 6:30 pm ET on Thursday, October 22 , 2015) "Mixture of Insulin Monomers, Dimers and Hexamers Demonstrated by Sedimentation Velocity Analysis Supports Bi-Phasic Ultra-Rapid-Acting and Basal Profile of Concentrated Human Insulin Formulation BIOD-531" will detail the molecular mechanism for the unique, bi-phasic profile of BIOD-531, the Company's proprietary, potentially best-in-class, ultra-rapid acting prandial/basal insulin candidate.

The poster presentation (4:00 pm - 6:30 pm ET on Thursday, October 22 , 2015) "Biodel's Glucagon Emergency Management (GEM) Auto-Reconstitution Device Demonstrates Superior Usability Compared to Marketed Glucagon Kits in Human Factors Study" will present data from formative Human Factors Studies which demonstrate clear-cut superiority of the GEM device with regard to ease-of-use, overall performance and reduction in dosing errors in comparison with the currently marketed glucagon kits.

The poster presentation ( 4:45 pm - 7:15 pm ET on Friday, October 23, 2015) "Pharmacokinetic and Pharmacodynamic Modeling Predict Concentrated Biphasic Insulin BIOD-531 Is Suitable for Twice or Three Times Daily Dosing with No Dose Accumulation" will present mathematical modeling of the pharmacokinetic and pharmacodynamic profiles of BIOD-531. These models predict that BIOD-531 is well suited for user-friendly dosing paradigms that are already commonly used in clinical practice.

The presentation abstracts can be accessed by members through the association's website, www.diabetestechnology.org .

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that may be safer, more effective and more convenient for patients. Biodel's product candidates are developed by applying proprietary technologies to existing drugs in order to improve their therapeutic profiles. More information about Biodel is available at www.biodel.com .

Safe-Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements about future activities related to the clinical development plans for Biodel's product candidates, potential timing, design and outcomes of clinical trials and Biodel's ability to develop and commercialize its product candidates. Forward-looking statements represent Biodel's management's judgment regarding future events. All statements, other than statements of historical facts, including statements regarding Biodel's strategy, future operations, future clinical trial results, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. The words "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Biodel's forward-looking statements are subject to a number of known and unknown risks and uncertainties that could cause actual results, performance or achievements to differ materially from those described or implied in the forward-looking statements, including, but not limited to, the progress, timing or success of Biodel's research and development and clinical programs for Biodel's product candidates; Biodel's ability to conduct the development work necessary to finalize the formulation and design of Biodel's auto-reconstitution glucagon rescue product candidate, as well as the preclinical studies, clinical trials and manufacturing activities necessary to support the filing of a new drug application, or NDA, to the U.S. Food and Drug Administration, or FDA, for that product candidate; Biodel's ability to engage a strategic partner in the further development of Biodel's prandial ultra-rapid-acting insulin formulations, including BIOD-531, which uses regular human insulin, or RHI, as the active pharmaceutical ingredient, and Biodel's insulin analog-based formulations; the success of Biodel's formulation development work to improve the stability of Biodel's newer ultra-rapid-acting insulin analog-based formulations while maintaining the pharmacokinetic and injection site toleration characteristics associated with earlier formulations; the results of Biodel's real-time stability programs for Biodel's RHI-, insulin analog- and glucagon-based product candidates, including the reproducibility of earlier, smaller scale, stability studies and Biodel's ability to accurately project long term stability on the basis of accelerated testing; Biodel's ability to accurately anticipate technical challenges that the company may face in the development of Biodel's ultra-rapid-acting RHI- and insulin analog-based product candidates or Biodel's glucagon rescue product candidates; Biodel's ability to secure approval by the FDA for Biodel's product candidates under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act; Biodel's ability to enter into collaboration arrangements for the commercialization of Biodel's product candidates and the success or failure of any such collaborations into which the company enters, or Biodel's ability to commercialize its product candidates on its own; Biodel's ability to enforce Biodel's patents for Biodel's product candidates and Biodel's ability to secure additional patents for Biodel's product candidates; and other factors identified in our most recent annual report on Form 10-K for the fiscal year ended September 30, 2014 and other subsequent filings with the Securities and Exchange Commission. The company disclaims any obligation to update any forward-looking statements as a result of events occurring after the date of this press release.

BIOD-G

CONTACT: Clayton Robertson, Trout Group +1 (646) 378 2964

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 258

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 334

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 333

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 282

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 546

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 461

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 466

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 289

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 411

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 335

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading

Top 5 Most Recently Viewed Articles

OneStream Shines as a 5-Time Leader in 2025 Gartner Magic Quadrant

Updated Category News Views 232

OneStream Recognized as a Leader in Financial Planning Software OneStream has achieved significant recognition in the financial planning software landscape by being named a leader in the 2025 Gartner Magic Quadrant. This achievement reflects their exceptional performance in both the Ability to Execute and Completeness of Vision categories. As businesses strive to...

Continue Reading
U.S. Bancorp Welcomes New Head of Consumer Payments Team

Updated Category News Views 307

U.S. Bancorp Appoints New Head of Consumer Payments U.S. Bancorp (BVMF: USBC34) (NYSE: USB) has made a significant move in its leadership with the appointment of Courtney Kelso as the senior executive vice president and head of Payments: Consumer and Small Business (PCS). This announcement underscores U.S. Bancorp's commitment to enhancing its consumer payment solutions...

Continue Reading
The Incredible Growth of Amphenol: A 20-Year Journey

Updated Category News Views 171

Exploring Amphenol's Long-Term Investment Potential Amphenol (NYSE: APH) has shown impressive returns in the stock market over the last two decades. With an average annual return of 22.23%, it has outperformed many market indices by 13.37% on an annualized basis. As of now, Amphenol boasts a market capitalization of approximately $167.52 billion, showcasing its stability...

Continue Reading
ASTM Announces Enhanced Direct Access to Cutting-Edge Platform

Updated Category News Views 361

ASTM's Enhanced Direct Access to Compass Platform Change in reseller relationship invites direct access through ASTM Compass. To better serve its customers' growing demand for advanced digital formats and efficient workflows, ASTM International is shifting its focus to direct sales. This decision comes as they will no longer continue their long-standing reseller...

Continue Reading
Berry Corporation Enhances Financial Framework with Refinancing

Updated Category News Views 108

Berry Corporation's Strategic Refinancing Initiative Berry Corporation (NASDAQ: BRY) has made headlines with the significant completion of a comprehensive refinancing strategy aimed at strengthening its financial foundation. This move, which occurred recently, marks a pivotal moment for the company, enhancing its capital and liquidity and enabling the firm to accelerate...

Continue Reading